{
    "clinical_study": {
        "@rank": "16713", 
        "arm_group": [
            {
                "arm_group_label": "Regorafenib", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Neomycin", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the effect of neomycin on the pharmacokinetics (PK) of regorafenib in healthy\n      male subjects"
        }, 
        "brief_title": "Effect of Neomycin on the Pharmacokinetics of Regorafenib", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion:\n\n          -  Healthy male subjects\n\n          -  Age: 18 to 45 years (inclusive) at the first screening examination/visit\n\n          -  Body mass index (BMI): above/equal 18 and below 30 kg / m\u00b2\n\n          -  Confirmation of the subject's health insurance coverage prior to the first screening\n             examination/visit\n\n          -  Subjects enrolled in this study must use adequate barrier birth control measures\n             prior to, during the course of the study, and 3 months after the last administration\n             of regorafenib. An adequate contraception includes the use of condoms or a vasectomy.\n             In addition, adequate birth control measures for the subject's partner is required,\n             such as a hormonal contraception with implants or combined oral contraceptives,\n             certain intrauterine devices, bilateral tubal ligation, or hysterectomy.\n\n        Exclusion:\n\n          -  Known or suspected hypersensitivity to regorafenib and/or neomycin\n\n          -  Any illness or medical condition that is unstable or could jeopardize the safety of\n             the subject and his compliance in the study\n\n          -  Clinically significant illness within 30 days prior to Day 1, Period 1.\n\n          -  Regular use of medicines at the time of screening, including herbal supplements and\n             high dose vitamins\n\n          -  Smoking; however, former smokers who have stopped smoking at least 3 months before\n             the first study drug administration may be included\n\n          -  Clinically relevant findings in the electrocardiogram (ECG)\n\n          -  Clinically relevant findings in the complete physical examination\n\n          -  Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus\n             antibodies (anti-HCV), human immune deficiency virus antibodies (anti-HIV 1+2) at\n             screening.\n\n          -  Positive urine drug screening"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02001909", 
            "org_study_id": "16675", 
            "secondary_id": "2013-001721-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "Regorafenib", 
                "description": "single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days", 
                "intervention_name": "Regorafenib (Stivarga, BAY73-4506)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Neomycin", 
                "description": "1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.", 
                "intervention_name": "Neomycin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Neomycin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Regorafenib", 
            "Neomycin", 
            "Cancer", 
            "Pharmacokinetics", 
            "Safety"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "13353"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Single-center, Open-label, Non-randomized, Two-period Sequential Treatment Study to Assess the Effect of Neomycin on the Pharmacokinetics of Regorafenib in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC (area under the plasma concentration vs. time curve) for regorafenib", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose"
            }, 
            {
                "measure": "Cmax (maximum drug concentration) for regorafenib", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02001909"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUC(0-24) (area under the plasma concentration vs. time curve) for regorafenib", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose"
            }, 
            {
                "measure": "AUC(0-tlast) (area under the plasma concentration vs. time curve) for regorafenib", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose"
            }, 
            {
                "measure": "AUC (area under the plasma concentration vs. time curve) for BAY75-7495 (M-2) and BAY81-8752 (M-5)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose"
            }, 
            {
                "measure": "Cmax (maximum drug concentration) for M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose"
            }, 
            {
                "measure": "tmax (time to reach maximum drug concentration in plasma after single dose) for regorafenib, M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose"
            }, 
            {
                "measure": "tlast (time of last concentration above lower limit of quantification) for regorafenib, M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose"
            }, 
            {
                "measure": "t1/2 (half-life associated with the terminal slope) for regorafenib, M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose"
            }, 
            {
                "measure": "AE,ur(0-72) (amount of drug excreted via urine during the collection interval 0-72 hours post administration) for metabolites BAY86-6651 (M-7) and BAY86-6652 (M-8)", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours post dose"
            }, 
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after last dose"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}